Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia

Avis, Hans J.; Hutten, Barbara A.; Gagné, Claude; Langslet, Gisle; McCrindle, Brian W.; Wiegman, Albert; Hsia, Judith; Kastelein, John J.P.; Stein, Evan A.

doi:10.1016/j.jacc.2009.10.042

Cited by 140 publications

(78 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, an increasing number of clinical studies have demonstrated the safety and efficacy of statin therapy in pediatric to adolescent patients with heterozygous FH; in children with heterozygous FH, simvastatin improved endothelial function, and 2-year pravastatin therapy reduced carotid IMT 43) . With respect to safety, several studies involving approximately 200 adolescent patients with heterozygous FH, aged 8 years or older, reported that short-term (2 years or less) therapy with lovastatin, simvastatin, pravastatin, or rosuvastatin effectively decreased LDL-C without influencing development, sexual maturation, testis volume, and blood gonadotropin and liver/muscular enzyme levels [44][45][46][47] . Based on these findings, statin therapy may be chosen when thickening of the Achilles tendon or an increase in the IMT is observed in children with FH; however, drug therapy for FH in children should be under cautious and extensive guidance by specialists.…”

Section: Drug Therapymentioning

confidence: 99%

Guidelines for the Management of Familial Hypercholesterolemia

Harada‐Shiba

Arai

Oikawa

et al. 2012

JAT

166

164

View full text Add to dashboard Cite

Familial hypercholesterolemia (FH) is a highly prevalent autosomal dominant hereditary disease, generally characterized by three major signs, hyper-low-density-lipoprotein (LDL) cholesterolemia, tendon/skin xanthomas and premature coronary artery disease (CAD). Because the risk of CAD is very high in these patients, they should be identified at an early stage of their lives and started on intensive treatment to control LDL-cholesterol. We here introduce a new guideline for the management of FH patients in Japan intending to achieve better control to prevent CAD. Diagnostic criteria for heterozygous FH are 2 or more of 1) LDL-cholesterol ≥ 180 mg/dL, 2) tendon/skin xanthoma(s), and 3) family history of FH or premature CAD within second degree relatives, for adults; and to have both 1) LDL-cholesterol ≥ 140 mg/dL and 2) family history of FH or premature CAD within second degree relatives, for children. For the treatment of adult heterozygous FH, intensive lipid control with statins and other drugs is necessary. Other risks of CAD, such as smoking, diabetes mellitus, hypertension etc., should also be controlled strictly. Atherosclerosis in coronary, carotid, or peripheral arteries, the aorta and aortic valve should be screened periodically. FH in children, pregnant women, and women who wish to bear a child should be referred to specialists. For homozygotes and severe heterozygotes resistant to drug therapies, LDL apheresis should be performed. The treatment cost of homozygous FH is authorized to be covered under the program of Research on Measures against Intractable Diseases by the Japanese Ministry of Health, Labour, and Welfare.

show abstract

Section: Drug Therapymentioning

confidence: 99%

Guidelines for the Management of Familial Hypercholesterolemia

Harada‐Shiba

Arai

Oikawa

et al. 2012

JAT

166

164

View full text Add to dashboard Cite

show abstract

“…high baseline LDL-C. 22 When discussing the treatment targets in FH children, the European consensus on FH recommends in children LDL-C <135 mg/dL (≈3.5 mmol/L) as a target for both homozygous and heterozygous FH, regardless of age. 4 The further recommendation is that the presence of very high LDL-C or additional cardiovascular risk factors may lower this target or the age at the beginning of the statin therapy.…”

Section: Reiner Diagnosis Of Atherosclerosis In Children With Fh 235mentioning

confidence: 99%

Impact of Early Evidence of Atherosclerotic Changes on Early Treatment in Children With Familial Hypercholesterolemia

Reiner

2014

Circulation Research

View full text Add to dashboard Cite

“…Podem diminuir o LDL-c em cerca de 30% e aumentar o HDL-c em 5%, e consequentemente atenuar o espessamento médio-intimal e melhorar a função endotelial [176][177][178][179][180][181] (Classe I, Nível A). Em que pesem essas considerações, não há evidências suficientes para consenso de quando começar estatinas na infância ou qual a meta de LDL-c a ser alcançada nessa faixa etária 182 (Classe IIb, Nível B).…”

Section: Estatinasunclassified